ClinicalTrials.gg
CompletedNCT01212757PALACE2Updated May 6, 2020Results posted

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

A Phase 3 interventional study of Apremilast 20mg and Apremilast 30mg in Psoriatic Arthritis, sponsored by Amgen. Completed at 98 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-06.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
4th of 17
488 · median 219
Started
2010
with 3 others
Phase 3
8 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Read the detailed description

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Psoriasis
  • Arthritis
  • Psoriatic Arthritis
  • inflammation
  • skin condition
  • inflammatory cells
  • apremilast
  • CC-10004
  • phosphodiesterase type 4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged ≥ 18 years at time of consent.
  • Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.
  • Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at time of screening.
  • Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)
  • May not have axial involvement alone
  • Concurrent Treatment allowed with methotrexate, leflunomide, or sulfasalazine
  • Have ≥ 3 swollen AND ≥ 3 tender joints.
  • Males \& Females must use
  • Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral allowed.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding.
  • History of allergy to any component of the product.
  • surface antigen and/or antibody positive at screening.
  • Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Apremilast 20mg

    20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase

    Drug: Apremilast 20mg

  • Experimental
    Apremilast 30mg

    30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily

    Drug: Apremilast 30mg

  • Placebo comparator
    Placebo + 20 mg Apremilast

    Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16

    Drug: Placebo + 20 mg Apremilast

  • Placebo comparator
    Placebo + 30 mg Apremilast

    Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

    Drug: Placebo + 30 mg Apremilast

Interventions

  • Apremilast 20 mg twice daily, orally

    Also known as: CC-10004

  • Apremilast 30 mg twice daily, orally

    Also known as: CC-10004

  • DrugPlacebo + 20 mg Apremilast

    Placebo + 20 mg Apremilast

    Also known as: Placebo, CC-10004

  • DrugPlacebo + 30 mg Apremilast

    Placebo + 30 mg Apremilast

    Also known as: Placebo, CC-10004

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

    Percentage of participants with an ACR20 response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 16

  2. Percentage of Participants With an ACR 20 Response at Week 24

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 24

  4. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  5. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: - 78 tender joint count, - 76 swollen joint count, - Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; - Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 16

  6. Change From Baseline in Patient's Assessment of Pain at Week 16

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 16

  7. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  8. Change From Baseline in Dactylitis Severity Score at Week 16

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  9. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: - 28 tender joint count (TJC), - 28 swollen joint count (SJC), - Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; - Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 16

  10. Change From Baseline in the Disease Activity Score (DAS28) at Week 16

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: - 28 tender joint count - 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; - C-reactive protein (CRP) - Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 16

  11. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  12. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  13. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Patient's Assessment of Pain at Week 24

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 24

  15. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  16. Change From Baseline in Dactylitis Severity Score at Week 24

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  17. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

    Time frame: Baseline and Week 24

  18. Change From Baseline in the Disease Activity Score (DAS28) at Week 24

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 24

  19. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  20. Percentage of Participants With MASES Improvement ≥ 20% at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  21. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  22. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 16

  23. Percentage of Participants With MASES Improvement ≥ 20% at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  24. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  25. Percentage of Participants With Good or Moderate EULAR Response at Week 24

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 24

  26. Percentage of Participants With a ACR 50 Response at Week 16

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

    Time frame: Baseline and Week 16

  27. Percentage of Participants With an ACR 70 Response at Week 16

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

    Time frame: Baseline and Week 16

  28. Percentage of Participants With an ACR 50 Response at Week 24

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

    Time frame: Baseline and Week 24

  29. Percentage of Participants With a ACR 70 Response at Week 24

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

    Time frame: Baseline and Week 24

  30. Percentage of Participants Achieving a MASES Score of Zero at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 16

  31. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 16

  32. Percentage of Participants Achieving a MASES Score of Zero at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Week 24

  33. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Week 24

  34. Percentage of Participants With a ACR 20 Response at Week 52

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  35. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 52

  36. Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  37. Percentage of Participants With a Modified PsARC Response at Week 52

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  38. Change From Baseline in the Patient Assessment of Pain at Week 52

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 52

  39. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 52

  40. Change From Baseline in the Dactylitis Severity Score at Week 52

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 52

  41. Change From Baseline in the CDAI Score at Week 52

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 52

  42. Change From Baseline in the DAS28 at Week 52

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 52

  43. Change From Baseline in the FACIT-Fatigue Scale Score at Week 52

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  44. Percentage of Participants With MASES Improvement ≥ 20% at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  45. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  46. Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 52

  47. Percentage of Participants With an ACR 50 Response at Week 52

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  48. Percentage of Participants With an ACR 70 Response at Week 52

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  49. Percentage of Participants Achieving a MASES Score of Zero at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  50. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Week 52

  51. Number of Participants With Treatment Emergent Adverse Events During the Placebo-Controlled Phase

    A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event

    Time frame: Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)

  52. Number of Participants With TEAEs During the Apremilast-Exposure Period

    A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event

    Time frame: Week 0 to week 260; overall median duration of exposure to apremilast 20 mg and 30 mg BID was 198 weeks

07

Results

Posted May 19, 2014

Participant flow

This study was a multicenter study with 84 sites from the United States, Canada, Europe, Russia, Australia, South Africa and Taiwan.

Placebo-controlled Phase (Week 0 - 24)
Participant flow — Placebo-controlled Phase (Week 0 - 24)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started162163163000000
Received treatment159163162000000
Completed week 16148151149000000
Early escape at week 16885964000000
Completed143143142000000
Not completed192021000000
Withdrew: Adverse event4512000000
Withdrew: Lack of efficacy322000000
Withdrew: Withdrawal by subject793000000
Withdrew: Randomization error301000000
Withdrew: Lost to follow-up112000000
Withdrew: Protocol violation011000000
Withdrew: Other120000000
Active Treatment Phase (Weeks 24 - 52)
Participant flow — Active Treatment Phase (Weeks 24 - 52)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started01371344327412800
Completed01251143525342800
Not completed01220827000
Withdrew: Adverse event023102000
Withdrew: Lack of efficacy057402000
Withdrew: Non-compliance with study drug002000000
Withdrew: Withdrawal by subject037313000
Withdrew: Lost to follow-up010010000
Withdrew: Other011000000
Long-Term Safety Phase (Year 2)
Participant flow — Long-Term Safety Phase (Year 2)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started011910900005860
Completed01079500004851
Not completed012140000109
Withdrew: Miscellaneous000000001
Withdrew: Adverse event011000022
Withdrew: Lack of efficacy042000040
Withdrew: Withdrawal by subject079000046
Withdrew: Lost to follow-up002000000
Long-Term Safety Phase (Year 3)
Participant flow — Long-Term Safety Phase (Year 3)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started01079500004851
Completed0898400004246
Not completed01811000065
Withdrew: Adverse event041000020
Withdrew: Lack of efficacy085000031
Withdrew: Non-compliance with study drug001000000
Withdrew: Withdrawal by subject051000011
Withdrew: Lost to follow-up000000001
Withdrew: Protocol violation010000000
Withdrew: Miscellaneous003000002
Long-Term Safety Phase (Year 4)
Participant flow — Long-Term Safety Phase (Year 4)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0898400004146
Completed0807700003739
Not completed097000047
Withdrew: Miscellaneous020000001
Withdrew: Adverse event012000011
Withdrew: Lack of efficacy022000011
Withdrew: Withdrawal by subject042000013
Withdrew: Death001000001
Withdrew: Lost to follow-up000000010
Long-Term Safety Phase (Year 5)
Participant flow — Long-Term Safety Phase (Year 5)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg (Long-Term Safety Phase)Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0807700003839
Completed0726900003337
Not completed088000052
Withdrew: Withdrawal by subject033000011
Withdrew: Adverse event022000020
Withdrew: Lack of efficacy012000021
Withdrew: Non-compliance with study drug010000000
Withdrew: Miscellaneous011000000

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

Percentage of participants with an ACR20 response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1618.937.432.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0060 · Adjusted difference: 13.4 · 95% CI 4.0 to 22.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% confidence interval (CI) is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0002 · Adjusted difference: 18.7 · 95% CI 9.1 to 28.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 16-0.053 ± 0.0358-0.157 ± 0.0351-0.193 ± 0.0354
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0042 · Ls mean difference: -0.140 · 95% CI -0.236 to -0.045Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0320 · Ls mean difference: -0.104 · 95% CI -0.199 to -0.009Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With an ACR 20 Response at Week 24

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 20 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 20 Response at Week 2415.731.324.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0394 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 9.2 · 95% CI 0.5 to 17.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0009 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Adjusted difference: 15.7 · 95% CI 6.7 to 24.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24-0.085 ± 0.0377-0.165 ± 0.0370-0.206 ± 0.0372
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0191 · Ls mean difference: -0.121 · 95% CI -0.222 to -0.020Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1179 · Ls mean difference: -0.080 · 95% CI -0.180 to 0.020Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 160.81 ± 0.6782.17 ± 0.6642.91 ± 0.671
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0237 · Ls mean difference: 2.10 · 95% CI 0.28 to 3.92Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1388 · Ls mean difference: 1.36 · 95% CI -0.44 to 3.15Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: - 78 tender joint count, - 76 swollen joint count, - Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; - Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 1633.347.948.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0065 · Adjusted difference: 14.9 · 95% CI 4.3 to 25.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0071 · Adjusted difference: 14.7 · 95% CI 4.1 to 25.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 16

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 16
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 16-7.0 ± 1.93-12.5 ± 1.89-11.9 ± 1.90
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0648 · Ls mean difference: -4.9 · 95% CI -10.0 to 0.3Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0347 · Ls mean difference: -5.5 · 95% CI -10.6 to -0.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16-1.0 ± 0.29-0.9 ± 0.28-1.4 ± 0.29
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.3496 · Ls mean difference: -0.4 · 95% CI -1.2 to 0.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.8874 · Ls mean difference: 0.1 · 95% CI -0.7 to 0.8Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 16

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 16-1.1 ± 0.28-0.8 ± 0.26-1.3 ± 0.26
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.5438 · Ls mean difference: -0.2 · 95% CI -1.0 to 0.5Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.3759 · Ls mean difference: 0.3 · 95% CI -0.4 to 1.0Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: - 28 tender joint count (TJC), - 28 swollen joint count (SJC), - Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; - Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16-3.30 ± 0.871-7.75 ± 0.851-6.81 ± 0.869
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0035 · Ls mean difference: -3.51 · 95% CI -5.86 to -1.16Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0002 · Ls mean difference: -4.45 · 95% CI -6.76 to -2.14Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 16

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: - 28 tender joint count - 28 swollen joint count, which do not include the distal interphalangeal (DIP) joints, the hip joint, or the joints below the knee; - C-reactive protein (CRP) - Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 16-0.27 ± 0.082-0.74 ± 0.080-0.67 ± 0.080
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0004 · Ls mean difference: -0.40 · 95% CI -0.61 to -0.18Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.47 · 95% CI -0.68 to -0.25Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 160.63 ± 0.7240.91 ± 0.7122.75 ± 0.715
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0318 · Ls mean difference: 2.12 · 95% CI 0.19 to 4.06Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.7803 · Ls mean difference: 0.27 · 95% CI -1.65 to 2.20Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 241.44 ± 0.6882.97 ± 0.6733.30 ± 0.679
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0473 · Ls mean difference: 1.86 · 95% CI 0.02 to 3.70Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0997 · Ls mean difference: 1.53 · 95% CI -0.29 to 3.35Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 2424.539.932.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1195 (The 2-sided p-value is based on the CMH test adjusting for baseline DMARD use.) · Adjusted difference: 7.8 · 95% CI -1.9 to 17.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0026 · Adjusted difference: 15.5 · 95% CI 5.6 to 25.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 24

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 24
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 24-8.0 ± 1.90-11.5 ± 1.86-9.7 ± 1.88
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.5067 · Ls mean difference: -1.7 · 95% CI -6.8 to 3.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.1762 · Ls mean difference: -3.5 · 95% CI -8.5 to 1.6Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24-0.9 ± 0.29-0.9 ± 0.28-1.3 ± 0.29
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.2719 · Ls mean difference: -0.4 · 95% CI -1.2 to 0.3Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.9727 · Ls mean difference: -0.0 · 95% CI -0.8 to 0.7Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 24

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 24-1.1 ± 0.27-0.9 ± 0.25-1.4 ± 0.26
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.3705 · Ls mean difference: -0.3 · 95% CI -1.0 to 0.4Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.6777 · Ls mean difference: 0.1 · 95% CI -0.6 to 0.8Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-3.21 ± 0.884-7.71 ± 0.864-6.35 ± 0.878
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0097 · Ls mean difference: -3.14 · 95% CI -5.52 to -0.76Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0002 · Ls mean difference: -4.50 · 95% CI -6.85 to -2.16Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 24

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) at Week 24-0.27 ± 0.084-0.73 ± 0.082-0.65 ± 0.083
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0011 · Ls mean difference: -0.38 · 95% CI -0.60 to -0.15Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0001 · Ls mean difference: -0.45 · 95% CI -0.68 to -0.23Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 240.52 ± 0.7210.68 ± 0.7102.65 ± 0.713
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0303 · Ls mean difference: 2.14 · 95% CI 0.20 to 4.07Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.8704 · Ls mean difference: 0.16 · 95% CI -1.76 to 2.08Based on an analysis of covariance (ANCOVA) model with treatment group and baseline DMARD use as factors, and the baseline value as a covariate.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 1652.954.256.4
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.6022 · Adjusted difference: 3.6 · 95% CI -9.9 to 17.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.8462 · Adjusted difference: 1.3 · 95% CI -12.1 to 14.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 1659.162.361.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.7337 · Adjusted difference: 2.8 · 95% CI -13.3 to 18.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.6881 · Adjusted difference: 3.3 · 95% CI -12.7 to 19.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 1631.453.448.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0014 · Adjusted difference: 17.5 · 95% CI 7.0 to 27.9Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0001 · Adjusted difference: 22.1 · 95% CI 11.7 to 32.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 2451.057.057.4
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.3376 · Adjusted difference: 6.6 · 95% CI -6.8 to 20.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3756 · Adjusted difference: 6.1 · 95% CI -7.2 to 19.4Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 2462.168.868.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.3959 · Adjusted difference: 6.8 · 95% CI -8.7 to 22.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3941 · Adjusted difference: 6.8 · 95% CI -8.7 to 22.4Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the Cochran-Mantel-Haenszel (CMH) weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With Good or Moderate EULAR Response at Week 24

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate EULAR Response at Week 2421.441.733.3
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0142 · Adjusted difference: 12.1 · 95% CI 2.6 to 21.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0001 · Adjusted difference: 20.5 · 95% CI 10.8 to 30.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 50 Response at Week 16

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 50 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 50 Response at Week 165.014.710.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0589 · Adjusted difference: 5.6 · 95% CI -0.2 to 11.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0034 · Adjusted difference: 9.8 · 95% CI 3.4 to 16.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 70 Response at Week 16

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 160.63.71.2
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.5620 · Adjusted difference: 0.6 · 95% CI -1.5 to 2.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.0570 · Adjusted difference: 3.1 · 95% CI -0.0 to 6.2Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With an ACR 50 Response at Week 24

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); o Patient's global assessment of disease activity (measured on a 100 mm VAS); o Physician's global assessment of disease activity (measured on a 100 mm VAS); o Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); o C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 248.814.111.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.3629 · Adjusted difference: 3.1 · 95% CI -3.5 to 9.6Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.1323 · Adjusted difference: 5.4 · 95% CI -1.5 to 12.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 70 Response at Week 24

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 70 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 70 Response at Week 243.15.52.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.7273 · Adjusted difference: -0.6 · 95% CI -4.3 to 3.0Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.2929 · Adjusted difference: 2.4 · 95% CI -2.0 to 6.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 1623.129.020.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.7023 · Adjusted difference: -2.2 · 95% CI -13.5 to 9.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3305 · Adjusted difference: 5.9 · 95% CI -5.9 to 17.7Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 1640.942.941.1
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.9698 · Adjusted difference: 0.3 · 95% CI -16.0 to 16.6Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.8205 · Adjusted difference: 1.9 · 95% CI -14.3 to 18.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 2424.029.922.8
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.8424 · Adjusted difference: -1.2 · 95% CI -12.7 to 10.3Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.3395 · Adjusted difference: 5.9 · 95% CI -6.0 to 17.8Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 2440.944.246.6
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.4811 · Adjusted difference: 5.9 · 95% CI -10.3 to 22.1Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.6965 · Adjusted difference: 3.3 · 95% CI -13.3 to 19.5Adjusted difference is the weighted average of the treatment differences across the 2 strata of baseline DMARD use with the CMH weights. The 2-sided 95% CI is based on a normal approximation to the weighted average.
SecondaryPercentage of Participants With a ACR 20 Response at Week 52

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 20 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 20 Response at Week 5253.3 (40.0 to 66.3)47.5 (34.6 to 60.7)52.9 (43.6 to 62.0)52.6 (43.1 to 61.9)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52-0.208 ± 0.4831-0.310 ± 0.5990-0.192 ± 0.5729-0.330 ± 0.5089
SecondaryChange From Baseline in the SF-36 Physical Functioning Scale Score at Week 52

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the SF-36 Physical Functioning Scale Score at Week 524.13 ± 9.1065.97 ± 9.6124.05 ± 8.7524.97 ± 9.656
SecondaryPercentage of Participants With a Modified PsARC Response at Week 52

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified PsARC Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified PsARC Response at Week 5278.3 (65.8 to 87.9)73.3 (60.3 to 83.9)72.4 (63.6 to 80.0)74.6 (65.6 to 82.3)
SecondaryChange From Baseline in the Patient Assessment of Pain at Week 52

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 52
Reported as:
Mean · mm
Change From Baseline in the Patient Assessment of Pain at Week 52
mmPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Patient Assessment of Pain at Week 52-15.6 ± 23.77-16.0 ± 24.48-13.5 ± 27.78-12.9 ± 26.54
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52-2.5 ± 4.41-2.5 ± 2.73-1.7 ± 3.12-2.1 ± 2.82
SecondaryChange From Baseline in the Dactylitis Severity Score at Week 52

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Dactylitis Severity Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Dactylitis Severity Score at Week 52-1.9 ± 1.14-2.1 ± 2.32-1.8 ± 1.98-1.8 ± 2.06
SecondaryChange From Baseline in the CDAI Score at Week 52

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the CDAI Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the CDAI Score at Week 52-13.66 ± 9.811-13.13 ± 13.148-12.03 ± 10.492-14.38 ± 11.531
SecondaryChange From Baseline in the DAS28 at Week 52

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the DAS28 at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the DAS28 at Week 52-1.18 ± 1.015-1.18 ± 1.366-1.11 ± 1.059-1.30 ± 1.033
SecondaryChange From Baseline in the FACIT-Fatigue Scale Score at Week 52

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the FACIT-Fatigue Scale Score at Week 521.97 ± 8.5444.95 ± 9.4142.45 ± 9.4814.38 ± 9.847
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 5272.5 (56.1 to 85.4)79.5 (63.5 to 90.7)70.0 (58.7 to 79.7)69.2 (57.8 to 79.2)
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 5295.7 (78.1 to 99.9)88.9 (70.8 to 97.6)80.7 (68.1 to 90.0)85.0 (73.4 to 92.9)
SecondaryPercentage of Participants Achieving Good or Moderate EULAR Response at Week 52

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 5270.064.568.067.5
SecondaryPercentage of Participants With an ACR 50 Response at Week 52

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 5230.5 (19.2 to 43.9)27.4 (16.9 to 40.2)26.7 (19.0 to 35.5)18.6 (12.1 to 26.9)
SecondaryPercentage of Participants With an ACR 70 Response at Week 52

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70 Response at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 5216.9 (8.4 to 29.0)14.3 (6.7 to 25.4)9.8 (5.1 to 16.4)6.8 (3.0 to 12.9)
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 5242.5 (27.0 to 59.1)41.0 (25.6 to 57.9)40.0 (29.2 to 51.6)37.2 (26.5 to 48.9)
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 5278.3 (56.3 to 92.5)77.8 (57.7 to 91.4)57.9 (44.1 to 70.9)65.0 (51.6 to 76.9)
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Placebo-Controlled Phase

A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event

Time frame:
Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events During the Placebo-Controlled Phase
ParticipantsPlaceboApremilast 20 mgApremilast 30 mg
Any TEAE7210696
Any Drug-Related TEAE285357
Any Severe TEAE5311
Any Serious TEAE (SAE)364
Any Drug-Related SAE031
Any TEAE Leading to Drug Interruption111631
Any TEAE Leading to Drug Withdrawal3512
Any TEAE Leading to Death000
SecondaryNumber of Participants With TEAEs During the Apremilast-Exposure Period

A treatment emergent adverse event (TEAE) is an AE with a start date on or after the date of the first dose of Investigational Product (IP). The severity of each adverse event (AE) and serious AE (SAE) was assessed by the investigator and graded based on a scale from Mild - mild symptoms to Severe AEs (non-serious or serious). A serious adverse event (SAE) is any AE which: * Resulted in death * Was life-threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Constituted an important medical event

Time frame:
Week 0 to week 260; overall median duration of exposure to apremilast 20 mg and 30 mg BID was 198 weeks
Reported as:
Number · participants
Number of Participants With TEAEs During the Apremilast-Exposure Period
participantsApremilast 20 mg (Pre-switch)Apremilast 20 mg/30 mg (Post-switch)Apremilast 30 mg BID
Any TEAE20253207
Any Drug-related TEAE1025100
Any Severe TEAE35237
Any Serious TEAE41541
Any Serious Drug-related TEAE616
Any TEAE Leading to Drug Interruption47465
Any TEAE Leading to Drug Withdrawal24330
Any TEAE Leading to Death002

Adverse events

Collected over AEs are reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants. AEs are reported for the Apremilast Exposure Period from Week 0 to Week 260; overall median exposure to apremilast was 198 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Weeks 0-24: Placebo (Placebo-Controlled Phase)—3/159 (1.9%)38/159 (23.9%)
Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)—6/163 (3.7%)73/163 (44.8%)
Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)—4/162 (2.5%)82/162 (50.6%)
APR Exposure Period Up to 5 Years: APR 20 mg—41/234 (17.5%)154/234 (65.8%)
APR Exposure Period Up to 5 Years: APR 20mg/30 mg—5/113 (4.4%)19/113 (16.8%)
APR Exposure Period Up to 5 Years: APR 30 mg—41/234 (17.5%)166/234 (70.9%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)APR Exposure Period Up to 5 Years: APR 20 mgAPR Exposure Period Up to 5 Years: APR 20mg/30 mgAPR Exposure Period Up to 5 Years: APR 30 mg
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1590/1630/1623/2340/1130/234
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/1590/1630/1621/2340/1133/234
DepressionPsychiatric disorders0/1591/1630/1623/2340/1131/234
Abscess soft tissueInfections and infestations0/1590/1630/1620/2341/1130/234
GastroenteritisInfections and infestations0/1590/1630/1620/2341/1130/234
OsteoarthritisMusculoskeletal and connective tissue disorders0/1590/1630/1622/2341/1131/234
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1590/1630/1621/2341/1130/234
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1590/1630/1620/2341/1130/234
Pelvic floor muscle weaknessReproductive system and breast disorders0/1590/1630/1620/2341/1130/234
Acute myocardial infarctionCardiac disorders0/1590/1630/1622/2340/1130/234
Most frequent other events
Showing 10 of 22
Most frequent other events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mg (Placebo- Controlled Phase)Weeks 0-24: Apremilast 30 mg (Placebo- Controlled Phase)APR Exposure Period Up to 5 Years: APR 20 mgAPR Exposure Period Up to 5 Years: APR 20mg/30 mgAPR Exposure Period Up to 5 Years: APR 30 mg
Upper respiratory tract infectionInfections and infestations6/15914/16311/16242/2344/11337/234
DiarrhoeaGastrointestinal disorders8/15918/16325/16233/2340/11340/234
NauseaGastrointestinal disorders3/15915/16326/16225/2341/11337/234
BronchitisInfections and infestations0/1595/1636/16219/2341/11330/234
NasopharyngitisInfections and infestations6/1599/1639/16228/2344/11330/234
HeadacheNervous system disorders7/1599/16318/16223/2340/11329/234
Back painMusculoskeletal and connective tissue disorders0/1595/1633/16222/2340/11314/234
HypertensionVascular disorders7/1594/1635/16221/2344/11322/234
Urinary tract infectionInfections and infestations2/1593/1631/16218/2344/11313/234
SinusitisInfections and infestations4/1594/1633/16217/2341/11315/234

Baseline characteristics

Full analysis set consisting of all participants who were randomized as specified in the protocol. Four participants who were randomized in error and did not receive any dose of investigational product are excluded.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean51.2 ± 10.9750.9 ± 11.8250.5 ± 11.2050.9 ± 11.32
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Female859595275
Male746867209
Duration of Psoriatic Arthritis
Duration of Psoriatic Arthritis(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean7.76 ± 8.2547.83 ± 8.6216.82 ± 7.5927.47 ± 8.163
08

Study locations

98 sites
  • Clinical and Translational Research Center of Alabama, PC
    Tuscaloosa, Alabama 35406, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • New England Research Associates, LLC
    Trumbull, Connecticut 6611, United States
  • Centre For Rheumatology, Immun. And Arthritis
    Fort Lauderdale, Florida 33334, United States
  • DMI Research
    Saint Petersburg, Florida 33710, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Arthritis and Rheumatology of Georgia
    Atlanta, Georgia 30342, United States
  • Michael Bukhalo MD SC
    Arlington Hts, Illinois 60005, United States
  • Associated Internal Medical Specialist, PC
    Battle Creek, Michigan 49015, United States
  • Advanced Rheumatology
    Lansing, Michigan 48910, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Research West Incorporated
    Kalispell, Montana 59901, United States
  • University of Rochester Medical Center
    Rochester, New York 14623, United States
  • Vital Research
    Greensboro, North Carolina 27408, United States
  • Unifour Medical Research Associatets LLC
    Hickory, North Carolina 28602, United States
  • Rheumatic Disease Associates
    Willow Grove, Pennsylvania 19090, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Baylor Research Institute
    Dallas, Texas 75246-1613, United States
  • Arthritis Care and Diagnostic Center
    Dallas, Texas 75321, United States
  • Luckster Enterprises
    San Antonio, Texas 78232, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98104, United States
  • Tacoma Center for Arthritis Research, PS
    Tacoma, Washington 98405, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • CHU Brugmann
    Bruxelles, 1020, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • University Hospital of Liege CHU Liege
    Liège, 4000, Belgium
  • Diagnostic and Consulting Centre 7
    Sofia, 1233, Bulgaria
  • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia
    Sofia, 1407, Bulgaria
  • 17 Diagnostic and Consulting Centre Sofia EOOD
    Sofia, 1505, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Ivan Rilski
    Sofia, 1612, Bulgaria
  • Diagnostic-Consultative Center Sveta Anna
    Sofia, 1709, Bulgaria
  • Diagnostic and Consulting Centre 4
    Varna, 9010, Bulgaria
  • Rheumatology Research Associates
    Edmonton, Alberta T5M 0H4, Canada
  • PerCuro Clinical Research
    Victoria, British Columbia V8P5P6, Canada
  • Anna Jaroszynska Private Practice
    Burlington, Ontario L7L0B7, Canada
  • William Bensen's Private Practice
    Hamilton, Ontario L8N1Y2, Canada
  • North Bay Dermatology Center
    North Bay, Ontario P1B 3Z7, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario K1H 1A2, Canada
  • Wilderman Medical Clinic
    Thornhill, Ontario L4J1W3, Canada
  • Darryl Toth's Private Practice
    Windsor, Ontario N8W 1E6, Canada
  • Revmatologie s.r.o.
    Brno, 638 00, Czechia
  • MEDIPONT PLUS s.r.o..
    Ceske Budejovice, 370 01, Czechia
  • L.K.N. Arthrocentrum s.r.o.
    Hlucin, 748 01, Czechia
  • ARTMEDI UPD s.r.o.
    Hostivice, 253 01, Czechia
  • Affidea Praha s.r.o
    Praha 11, 148 00, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka Ambulance
    Praha 4, 140 00, Czechia
  • Revmatologicka Ambulance
    Sokolov, 356 01, Czechia
  • PV - MEDICAL, s.r.o.
    Zlin, 760 01, Czechia
  • Parnu Hospital
    Pärnu, EE-80010, Estonia
  • East Tallinn Central Hospital
    Tallinn, EE-11412, Estonia
  • North Estonia Regional Hospital
    Tallinn, EE-13419, Estonia
  • Clinical Research Centre Ltd
    Tartu, 50106, Estonia
  • Tartu University Hospital
    Tartu, EE-51014, Estonia
  • Hopital Universitaire Dupuytren
    Limoges, 87042, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Fondation Hôpital Saint-Joseph
    Paris, 75014, France
  • Groupe Hospitalier Pitié- Salpétrière
    Paris, 75651, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Charite - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Klinikum der Johann-Wolfgang Goethe-Universität
    Frankfurt, 60590, Germany
  • Praxis Karin Rockwitz
    Goslar, 38642, Germany
  • Synexus Clinical Research GmbH
    Leipzig, 4103, Germany
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Principal SMO Kft.
    Makó, 6900, Hungary
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Ospedale Luigi Sacco
    Milano, 20157, Italy
  • Seconda Universita degli Studi di Napoli
    Napoli, 80130, Italy
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Universita di Pisa
    Pisa, 56126, Italy
  • Ospedale Civile Maggiore Borgo Trento
    Verona, 37126, Italy
  • NZOZ Osteo-Medic sc A. Racewicz J. Supronik
    Bialystok, 15-351, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej REUMED
    Lublin, 20-582, Poland
  • Instytut Reumatologii im. prof. dr hab. med. Eleonory Reicher
    Warsaw, 02-637, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, 00-909, Poland
  • Synexus SCM Sp. z o.o.
    Wroclaw, 50-088, Poland
  • City Clinical Hospital #1 n.a. N.I.Pirogov
    Moscow, 119049, Russian Federation
  • City Clinical Hospital #5
    Nizhniy Novgorod, 603005, Russian Federation
  • St.Petersburg State Medical Academy n. a. I.I.Mechnikov
    St. Petersburg, 195067, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, 150062, Russian Federation
  • Nelson Mandela School Of Medicine
    Durban, 4091, South Africa
  • Greenacres Hospital
    Port Elizabeth, 6057, South Africa
  • Jacaranda Hospital
    Pretoria, 2, South Africa
  • Hospital Universitario de Canarias
    La Laguna, 38320, Spain
  • Hospital General Carlos Haya
    Málaga, 29009, Spain
  • Hospital Sierrallana
    Torrelavega, 39300, Spain
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Cathay General Hospital
    Taipei, 106, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • National Taiwan University Hospital
    Tapei, 10002, Taiwan
  • Basingstoke and North Hampshire Hospital
    Basingstoke, RG24 9NA, United Kingdom
  • Cannock Chase Hospital
    Cannock, WS11 5XY, United Kingdom
  • Chapel Allerton Hospital
    Leeds, LS7 4SA, United Kingdom
  • Poole Hospital
    Poole, BH 1 5JB, United Kingdom
  • Great Western Hospital
    Swindon, SN3 6BB, United Kingdom
09

References and documents

Publications

  • Cutolo M, Myerson GE, Fleischmann RM, Liote F, Diaz-Gonzalez F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376. Epub 2016 Jul 15. PubMed 27422893 ↗
  • Mease PJ, Gladman DD, Kavanaugh A, McGonagle D, Nash P, Guerette B, Nakasato P, Brunori M, Teng L, McInnes IB. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatol Ther. 2021 Dec;8(4):1677-1691. doi: 10.1007/s40744-021-00369-x. Epub 2021 Sep 18. PubMed 34536218 ↗
  • Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, McInnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res (Hoboken). 2020 Jun;72(6):814-821. doi: 10.1002/acr.24134. Epub 2020 May 8. PubMed 31909868 ↗
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3. PubMed 31077258 ↗
  • Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. PubMed 30018799 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jul 2012, 21 months.

Results were first posted in May 2014, 1 year 9 months after primary completion. A results delay was requested in May 2013.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 21 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Oct 1, 2010
StartActual
Sep 27, 2010
Primary completionActual
Jul 26, 2012
CompletionActual
Jan 25, 2017
Results delay requested
May 29, 2013
Results first posted
May 19, 2014
Last update
May 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01212757
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 1, 2010
Start date
Sep 27, 2010
Primary completion
Jul 26, 2012
Completion
Jan 25, 2017
Results posted
May 19, 2014
Last update
May 6, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion